Literature DB >> 17941276

Role of nitric oxide production in anaphylaxis and its relevance for the treatment of anaphylactic hypotension with methylene blue.

Paulo R B Evora1, Michael R Simon.   

Abstract

OBJECTIVE: To review the role of nitric oxide production in anaphylaxis. DATA SOURCES: We performed MEDLINE searches of the literature. In addition, some references known to the authors but not listed in MEDLINE, such as abstracts and a CD-ROM, were included. Finally, additional clinical details of the cases were provided by one of the authors. STUDY SELECTION: Primary reports were preferentially selected for inclusion. However, some secondary publications are also cited.
RESULTS: Histamine along with other mediators, such as leukotrienes, tumor necrosis factor, and platelet-activating factor, induce the production of nitric oxide. Nitric oxide can inhibit the release and effects of catecholamines. Sympathetic amines may inhibit production of nitric oxide. Studies in animals have demonstrated the generation of nitric oxide during anaphylaxis. Inhibition of nitric oxide synthase improves survival in an animal model of anaphylaxis. Nitric oxide causes vasodilation indirectly by increasing the activation of guanylyl cyclase, which then causes smooth muscle relaxation by increasing the concentration of smooth muscle cyclic guanosine monophosphate. Methylene blue is an inhibitor of guanylyl cyclase, which increases systemic vascular resistance and reverses shock in animal studies. The previously reported successful treatment with methylene blue of 11 patients with anaphylactic hypotension is reviewed.
CONCLUSION: Nitric oxide plays a significant role in the pathophysiology of anaphylaxis. Treatment with methylene blue should be considered in patients with anaphylactic hypotension that has not responded to other interventions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17941276     DOI: 10.1016/S1081-1206(10)60545-5

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  11 in total

Review 1.  Understanding the mechanisms of anaphylaxis.

Authors:  Richard D Peavy; Dean D Metcalfe
Journal:  Curr Opin Allergy Clin Immunol       Date:  2008-08

2.  Anaphylaxis with Latrodectus antivenin resulting in cardiac arrest.

Authors:  Christine M Murphy; Jeannie J Hong; Michael C Beuhler
Journal:  J Med Toxicol       Date:  2011-12

3.  Efficacy of methylene blue in an experimental model of calcium channel blocker-induced shock.

Authors:  David H Jang; Sean Donovan; Lewis S Nelson; Theodore C Bania; Robert S Hoffman; Jason Chu
Journal:  Ann Emerg Med       Date:  2014-10-23       Impact factor: 5.721

4.  Estrogen increases the severity of anaphylaxis in female mice through enhanced endothelial nitric oxide synthase expression and nitric oxide production.

Authors:  Valerie Hox; Avanti Desai; Geethani Bandara; Alasdair M Gilfillan; Dean D Metcalfe; Ana Olivera
Journal:  J Allergy Clin Immunol       Date:  2014-12-29       Impact factor: 10.793

5.  Main Properties of the THERAFLEX MB-Plasma System for Pathogen Reduction.

Authors:  Jerard Seghatchian; Wilhelm G Struff; Stefan Reichenberg
Journal:  Transfus Med Hemother       Date:  2011-01-27       Impact factor: 3.747

6.  High absolute bioavailability of methylene blue given as an aqueous oral formulation.

Authors:  Ingeborg Walter-Sack; Jens Rengelshausen; Heike Oberwittler; Juergen Burhenne; Olaf Mueller; Peter Meissner; Gerd Mikus
Journal:  Eur J Clin Pharmacol       Date:  2008-09-23       Impact factor: 2.953

7.  G-Proteins Agonists and NO/cGMP Blockers: Unexplored Frontiers in the Pharmaceutical Industry.

Authors:  Paulo Roberto B Evora
Journal:  Arq Bras Cardiol       Date:  2017-10       Impact factor: 2.000

8.  Severe Anaphylaxis to Volplex, a Colloid Solution during Cesarean Section: A Case Report and Review.

Authors:  K Karri; R Raghavan; J Shahid
Journal:  Obstet Gynecol Int       Date:  2009-05-26

9.  Nitric oxide inhibition strategies.

Authors:  Vivian Wai Chong Wong; Ethan Lerner
Journal:  Future Sci OA       Date:  2015

Review 10.  Pharmacological treatment options for mast cell activation disease.

Authors:  Gerhard J Molderings; Britta Haenisch; Stefan Brettner; Jürgen Homann; Markus Menzen; Franz Ludwig Dumoulin; Jens Panse; Joseph Butterfield; Lawrence B Afrin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-04-30       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.